Allergy Therapeutics plc (AIM:AGY)
London · Delayed Price · Currency is GBP · Price in GBX 5.28
+0.03 (0.48%)
Aug 17, 2026, 2:58 PM GMT
Allergy Therapeutics Ratios and Metrics
Market cap in millions GBP. Fiscal year is July - June.
Millions GBP. Fiscal year is Jul - Jun.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 17, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 332 | 379 | 250 | 7 | 134 | 160 | |
Market Cap Growth | -14.94% | 51.72% | 3402.67% | -94.66% | -16.71% | 80.14% |
Enterprise Value | 349 | 402 | 246 | 2 | 102 | 124 |
Last Close Price | 0.05 | 0.08 | 0.05 | 0.00 | 0.10 | 0.12 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 17, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
PE Ratio | - | - | - | - | - | 55.59 |
Forward PE | - | 63.31 | 63.31 | 63.31 | 63.31 | 63.31 |
PS Ratio | 5.80 | 6.88 | 4.53 | 0.12 | 1.84 | 1.90 |
PB Ratio | 78.24 | -13.44 | 33.95 | 3.45 | 3.54 | 3.31 |
P/TBV Ratio | 6784.85 | - | 93.58 | - | 4.08 | 3.67 |
P/FCF Ratio | - | - | - | - | - | 26.62 |
P/OCF Ratio | - | - | - | - | - | 18.68 |
PEG Ratio | - | 5.65 | 5.65 | 5.65 | 5.65 | 5.65 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 17, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
EV/Sales Ratio | 6.09 | 7.30 | 4.46 | 0.03 | 1.40 | 1.47 |
EV/EBITDA Ratio | - | - | - | - | - | 20.31 |
EV/EBIT Ratio | - | - | - | - | - | 31.62 |
EV/FCF Ratio | - | - | - | - | - | 20.60 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 17, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Debt / Equity Ratio | 6.30 | -2.13 | 4.21 | 17.42 | 0.28 | 0.23 |
Debt / EBITDA Ratio | - | - | - | - | - | 1.44 |
Debt / FCF Ratio | - | - | - | - | - | 1.85 |
Net Debt / Equity Ratio | 3.92 | -1.68 | 2.46 | 10.23 | -0.26 | -0.60 |
Net Debt / EBITDA Ratio | -0.53 | -1.81 | -0.56 | -0.64 | 0.98 | -4.76 |
Net Debt / FCF Ratio | -0.45 | -1.51 | -0.51 | -0.63 | 0.59 | -4.83 |
Asset Turnover | 0.80 | 0.82 | 0.83 | 0.85 | 0.90 | 0.97 |
Inventory Turnover | 2.13 | 1.93 | 2.09 | 2.29 | 2.09 | 2.11 |
Quick Ratio | 0.70 | 0.69 | 1.02 | 1.07 | 1.46 | 2.46 |
Current Ratio | 1.13 | 1.27 | 1.78 | 1.81 | 2.35 | 3.17 |
Return on Equity (ROE) | - | - | -819.81% | -216.27% | -31.93% | 6.25% |
Return on Assets (ROA) | -29.64% | -26.58% | -32.23% | -31.48% | -9.60% | 2.81% |
Return on Invested Capital (ROIC) | -163.21% | -86.61% | -141.18% | -138.02% | -52.41% | 16.12% |
Return on Capital Employed (ROCE) | -87.60% | -70.60% | -72.10% | -73.00% | -22.50% | 5.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 17, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Earnings Yield | -14.49% | -10.59% | -15.46% | -604.03% | -10.31% | 1.80% |
FCF Yield | -11.18% | -8.28% | -14.23% | -470.51% | -12.76% | 3.76% |
Buyback Yield / Dilution | -4.81% | -27.33% | -458.41% | -4.26% | 4.98% | -0.47% |